IL17A and neoplasm: Clinical studies have shown that in cancer patients, both IL-17-secreting Vδ2+ cells and IFN-γ-secreting Vδ1+ cells are present [119,120,121], and these two subsets exhibit distinct cytotoxic marker profiles in the tumor environment [122].